Washington: The top U.S. drug regulator is headed to India, which supplies an estimated 40 percent of the generic drugs sold in the U.S., to talk about quality issues after recent action against some Indian drug makers.
The U.S. Food and Drug Administration announced that Commissioner Margaret A. Hamburg, will travel to India Feb 10-18 "to further strengthen cooperation between the FDA and its Indian regulatory counterparts".
During her first official trip to India, intended "to highlight importance of ongoing collaboration on food and drug programmes", Hamburg will meet Indian policy and government leaders involved in the regulation of medical and food products exported to the U.S.
Besides Delhi, she will also visit Cochin and Mumbai.
"Indian regulators are important strategic partners to the FDA and regular engagement is essential," the FDA said noting currently, India is the second largest provider of finished drug products and the eighth largest exporter of food products to the U.S.
"The FDA's ongoing engagement with our regulatory counterparts in India is critical to our ability to effectively promote the health and safety of American and Indian consumers," Hamburg said.
"I look forward to enhancing our existing relationship and identifying additional opportunities for collaboration."
Also Read:
Post Strict Regulations, Govt Plans To Ease Clinical Trials Norms
The Most Unsafe Cities to Live In
Magazine : 
.jpg "Renewing Smiles, Restoring Confidence")
